Ex-Chief of Defence Force urges ACT Government to allow medical use of psychedelic-assisted psychotherapy
Mind Medicine Australia, June 2, 2022
Ex-Chief of the Defence Force, Admiral Chris Barrie AC, has urged the ACT Government to allow the medical use of psilocybin and MDMA assisted psychotherapies for patients suffering from treatment-resistant depression and treatment resistant post-traumatic stress disorder (PTSD).
Mind Medicine Australia welcomes consideration of changes to allow psychedelic therapy in the ACT
Mind Medicine Australia, May 11, 2022
Mind Medicine Australia has welcomed consideration by the ACT Health Minister, Rachel Stephen-Smith, and the ACT Mental Health Minister, Emma Davidson, of legislative changes to allow psychedelic therapy in the ACT to treat mental illness.
Mind Medicine Australia Lodges New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies for Patients with Treatment Resistant Mental Illnesses
Mind Medicine Australia, March 17, 2022
Australia is experiencing a severe mental health epidemic, and this crisis is getting worse. Unfortunately, existing treatments only lead to remission for a minority of patients with depression and post-traumatic stress disorder and the psychiatric pharmaceuticals can cause dependence and nasty side effects for some patients. For this reason, Mind Medicine Australia is again seeking to reschedule the medical use of psilocybin and MDMA as part of therapy from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard.
Why is an Australian life less worthy than a Canadian’s?
Mind Medicine Australia, February 9, 2022
Both Canada and Australia are battling a growing shadow pandemic of mental illness. Despite having world leading health care systems, both nations are facing an ever-increasing wave of mental illness, addictions and lives lost to suicide. On 4th January 2022, Health Canada announced that it will provide a pathway for physicians to obtain approvals for patients to access Psychedelic-Assisted Therapies through their Special Access Program. Australia has yet to implement a similar scheme.
New Polling by Mind Medicine Australia Reveals Over 60% of Australians Support Increased Access to Psychedelic Medicines
Mind Medicine Australia, February 7, 2022
Mind Medicine Australia (MMA) is delighted to announce the findings of a sentiment poll we initiated through Essential Research last week.
Mind Medicine Australia joins global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances
Mind Medicine Australia, January 13, 2022
Today Mind Medicine Australia joins in the launch of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances.
Emyria to expand Real World Data assets for MDMA-assisted therapy trials by incorporating wearables monitoring
Emyria (ASX: EMD ) Press Release, December 20, 2021
Emyria’s phase 2b MDMA-assisted therapy trial for severe Post Traumatic Stress Disorder (PTSD), EMDMA-001, developed with registered charity Mind Medicine Australia (MMA), will be the first program to incorporate Cydelic technology and is expected to be one of the first programs in the world to incorporate remote patient monitoring within MDMA-assisted therapy.
TGA says NO again to psychedelic-assisted therapies.
Mind Medicine Australia, December 15, 2021
Mind Medicine Australia’s Response to the Announcement of the TGA NOT to Reschedule the Medical Use of MDMA for Treatment Resistant PTSD and the Medical Use of Psilocybin for Treatment Resistant Depression as Part of Therapy.
Monash University announces establishment of the Neuromedicines Discovery Centre to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness
Mind Medicine Australia, November 10, 2021
We are delighted that Monash University has announced the establishment of the Neuromedicines Discovery Centre (NDC) to focus on psychedelic-assisted therapies for the treatment of mental illness. This initiative was developed from a proposal put to Monash University by Mind Medicine Australia and our advocacy work with key stakeholders.
Mind Medicine Australia Launches Australia’s First Book of Psychedelic Healing Stories
Mind Medicine Australia, October 18, 2021
Mind Medicine Australia (MMA) is releasing a new book sharing the psychedelic healing stories of 53 Australians, in their own words. Launched during Mental Health Month, this first Australian book of true stories further reinforces the life-changing and life-saving impact of psychedelic-assisted therapies for a range of mental illnesses and addictions.
Launching a Dedicated Training, Education and Clinical Services Organisation Focusing on Psychedelic Assisted Therapies for Mental Illness and the Developing Understanding of the Mind, Cognition and Human Consciousness
Mind Medicine Australia, October 12, 2021
Mind Medicine Australia (MMA) and Integrated Psychology and Medicine (IPM) are delighted to announce the establishment of a new training, education and clinical services organisation called Mind Medicine Training and Education (MMTE).
Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics in Treating Mental Health Crisis
Mind Medicine Australia, October 3, 2021
The findings of an expert panel reviewing the use of psychedelics in treating Australia’s mental health crisis, give strong support to such treatments being introduced at this stage on a case-by-case basis, under the supervision of the patient’s doctors and trained therapists.
TGA moves one step closer to rescheduling MDMA and Psilocybin in Australia
Mind Medicine Australia, October 1, 2021
Yesterday, the TGA released the Independent Review that it had commissioned on the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of key mental health disorders.
Mind Medicine Australia to host Australia’s Inaugural International Summit on Psychedelic Therapies for Mental Illness online in November 2021
Mind Medicine Australia, September 2, 2021
Mental health charity Mind Medicine Australia (MMA) is delighted to announce the inaugural International Summit on Psychedelic Therapies for Mental Illness and 2-day Introductory Workshop will take place between 17–20 November 2021 online.
Australia’s crisis of suffering accelerates while effective treatment remains blocked
Mind Medicine Australia, August 25, 2021
Mind Medicine Australia is urgently calling for the Federal and State governments to enable psychedelic-assisted therapies to be used to treat severely ill patients who desperately need safe and effective treatments.
TGA appoints Independent Expert Panel on MDMA and psilocybin
TGA, August 5, 2021
The Therapeutic Goods Administration (TGA) Scheduling Delegate (decision maker) has deferred the final decision on applications to down-schedule MDMA and psilocybin from schedule 9 (prohibited drug) to schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances. The Independent Expert Panel to undertake this review has now been established.
Mind Medicine Australia announces 10 scholarships to be made available to outstanding female health professionals from the Northern Rivers Region
Mind Medicine Australia, June 23, 2021
Mind Medicine Australia is delighted to announce that it will offer 10 scholarships for its Certificate in Psychedelic-Assisted Therapies (CPAT) for female psychiatrists, GPs, physicians, nurses, psychologists, psychotherapists, social workers, counsellors and occupational therapists in the Northern Rivers Shire of NSW.
Legislative changes to allow psychedelic-assisted therapy treatments for mental illness patients in the ACT if first approved by the TGA
Mind Medicine Australia, June 15, 2021
Mind Medicine Australia has proposed conservative legislative changes to allow psychedelic-assisted therapy to be used for the treatment of mental illness in the ACT where they have first been approved by the Therapeutic Goods Administration (TGA).
TGA Seeks Independent Review on Rescheduling of Psilocybin and MDMA as Part of Therapy in Medically Controlled Environments
Mind Medicine Australia, April 8, 2021
The TGA announced that the Scheduling Delegate has decided to seek further advice in relation to Mind Medicine Australia’s applications to reschedule psilocybin and MDMA as part of therapy in medically controlled environments.
Your Psychedelic Healing Stories Can Help Change and Save Lives
Mind Medicine Australia, March 24, 2021
We’re putting together a special book about psychedelics in Australia, the first of its kind – filled with incredible and inspirational stories of people who’ve changed their lives through psychedelic medicines like psilocybin and MDMA.